Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. Academic Article uri icon

Overview

abstract

  • PURPOSE: To report the influence of posttreatment prostate-specific antigen (PSA) nadir response at 2 years after external beam radiotherapy (RT) on distant metastases (DM) and cause-specific mortality (CSM). METHODS AND MATERIALS: Eight hundred forty-four patients with localized prostate cancer were treated with conformal RT. The median duration of follow-up was 9.1 years. A fixed landmark time point at 2 years was used to assess the influence of nadir PSA value as a time-dependent variable on long-term outcomes. RESULTS: Multivariate analysis demonstrated that nadir PSA

publication date

  • June 8, 2009

Research

keywords

  • Prostate-Specific Antigen
  • Prostatic Neoplasms
  • Radiotherapy, Conformal

Identity

Scopus Document Identifier

  • 71649102589

Digital Object Identifier (DOI)

  • 10.1016/j.ijrobp.2008.12.067

PubMed ID

  • 19515504

Additional Document Info

volume

  • 75

issue

  • 5